What is Gyre Therapeutics, Inc.'s EPS (diluted)?

Gyre Therapeutics, Inc. (GYRE) reported EPS (diluted) of -$0.10 in Q1 2026.

What is the long-term trend for Gyre Therapeutics, Inc.'s EPS (diluted)?

Over 2 years (2021 to 2024), Gyre Therapeutics, Inc.'s EPS (diluted) has grown at a -86.8% compound annual growth rate (CAGR), from -$2.87 to $0.05.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Gyre Therapeutics, Inc. GYRE EPS (Diluted)

EPS (Diluted) at other companies

Eli LillyLLY

$8.26+170%

Madrigal Pharmaceuticals, Inc.MDGL

-$3.25-24.5%

Viking TherapeuticsVKTX

-$1.37-234%

Theravance BiopharmaTBPH

-$0.10+63.0%

Rigel PharmaceuticalsRIGL

$0.44-30.2%

Zevra Therapeutics, Inc.ZVRA

$0.60+1,100%

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s EPS (diluted)?: Gyre Therapeutics, Inc. (GYRE) reported EPS (diluted) of -$0.10 in Q1 2026.
What is the long-term trend for Gyre Therapeutics, Inc.'s EPS (diluted)?: Over 2 years (2021 to 2024), Gyre Therapeutics, Inc.'s EPS (diluted) has grown at a -86.8% compound annual growth rate (CAGR), from -$2.87 to $0.05.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.